Synergistic effect of intratumoral IL-12 and TNF-α microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells

Surgery

Volumn 142, Issue 5, 2007, Pages 749-760

  Sabel, Michael S ^a   Arora, Alisha ^a   Su, Gang ^a   Mathiowitz, Edith ^b   Reineke, Joshua J ^b   Chang, Alfred E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER; GAMMA INTERFERON; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MICROSPHERE; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; FEMALE; IMMUNE RESPONSE; IMMUNE STATUS; LUNG METASTASIS; LYMPHOCYTE TRANSFER; MONOTHERAPY; MOUSE; NATURAL KILLER CELL; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-12; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MELANOMA; MICE; MICE, INBRED C57BL; MICROSPHERES; NEOPLASM TRANSPLANTATION; SARCOMA; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35548950222     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2007.05.008     Document Type: Article

References (44)

1. Crittenden M.R., Thanarajasingam U., Vile R.G., and Gough M.J. Intratumoral immunotherapy: using the tumour against itself. Immunology 114 (2005) 11-22
2. Egilmez N.K., Jong Y.S., Sabel M.S., et al. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res 60 (2000) 3832-3837
3. Sabel M.S., Hill H., Jong Y.S., et al. Neoadjuvant therapy with interleukin-12-loaded polylactic acid microspheres reduces local recurrence and distant metastases. Surgery 130 (2001) 470-478
4. Hill H.C., Conway Jr. T.F., Sabel M.S., et al. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res 62 (2002) 7254-7263
5. Sabel M.S., Skitzki J., Stoolman L., et al. Intratumoral IL-12 and TNF-alpha-loaded microspheres lead to regression of breast cancer and systemic antitumor immunity. Ann Surg Oncol 11 (2004) 147-156
6. Arora A., Su G., Mathiowitz E., et al. Neoadjuvant intratumoral cytokine-loaded microspheres are superior to postoperative autologous cellular vaccines in generating systemic anti-tumor immunity. J Surg Oncol 94 (2006) 403-412
7. Barth R.J., Bock S.N., Mulé J.J., and Rosenberg S.A. Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes. J Immunol 144 (1990) 1531-1537
8. Shu S., and Rosenberg S.A. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells. J Immunol 135 (1985) 2895-2903
9. Hart I.R. The selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol 97 (1979) 587-600
10. Brunda M.J. Interleukin-12. J Leukoc Biol 55 (1994) 280-288
11. Trinchieri G. Interleukin-12: A cytokine at the interface of inflamation and immunity. Adv Immunol 70 (1998) 83-243
12. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3 (2003) 133-146
13. Banks R.E., Patel P.M., and Selby P.J. Interleukin 12: a new clinical player in cytokine therapy. Br J Cancer 71 (1995) 655-659
14. Scott P. IL-12: Initiation cytokine for cell-mediated immunity. Science 260 (1993) 496-497
15. Voest E.E., Kenyon B.M., O'Reilly M.S., et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87 (1995) 581-586
16. Leonard J.P., Sherman M.L., Fisher G.L., et al. Effects of single-dose interleukin-12 exposure on interleukin-12 associated toxicity and interferon-gamma production. Blood 90 (1997) 2541-2548
17. Atkins M.B., Robertson M.J., Gordon M., et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3 (1997) 409-417
18. Motzer R.J., Rakhit A., Thompson J.A., et al. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha-2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res 21 (2001) 257-263
19. Hurteau J.A., Blessing J.A., DeCesare S.L., and Creasman W.T. Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol Oncol 82 (2001) 7-10
20. Bajetta E., Del Vecchio M., Mortarini R., et al. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res 4 (1998) 75-85
21. Addison C.L., Bramson J.L., Hitt M.M., et al. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Ther 5 (1998) 1400-1409
22. Di Carlo E., Comes A., Basso S., et al. The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement. J Immunol 165 (2000) 3111-3118
23. Tamura T., Nishi T., Goto T., et al. Combination of IL-12 and IL-18 of electro-gene therapy synergistically inhibits tumor growth. Anticancer Res 23 (2003) 1173-1179
24. Tatsumi T., Huang J., Gooding W.E., et al. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res 63 (2003) 6378-6386
25. Lasek W., Feleszko W., Golab J., et al. Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor alpha in mice. Cancer Immunol Immunother 45 (1997) 100-108
26. Ostensen M.E., Thiele D.L., and Lipsky P.E. Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells. J Immunol 138 (1987) 4185-4191
27. Mocellin S., Rossi C.R., Pilati P., and Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 16 (2005) 35-53
28. Lasek W., Mackiewicz A., Czajka A., et al. Antitumor effects of the combination thearpy with TNF-alpha gene-modified tumor cells and interleukin 12 in a melanoma model in mice. Cancer Gene Ther 7 (2000) 1581-1590
29. Halin C., Gafner V., Villani M.E., et al. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res 63 (2003) 3202-3210
30. Taniguchi F., Yamagishi H., Fujuwara H., et al. Systemic administration of rIL-12 synergistically enhances the therapeutic effect of a TNF gene-transduced cancer vaccine. Gene Ther 5 (1999) 1677-1684
31. Melero I., Mazzolini G., Narvaiza I., et al. IL-12 gene therapy for cancer: in synergy with other immunotherapies. Trends Immunol 22 (2001) 113-115
32. Ogawa M., Umehara W.G., Yu W.G., et al. A critical role for a peritumoral stromal reaction in the induction of T-cell migration responsible for interleukin-12-induced tumor regression. Cancer Res 59 (1999) 1531-1538
33. Eggermont A.M., de Wilt J.H., and ten Hagen T.L. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncology 4 (2003) 429-437
34. Furrer M., Altermatt H.J., Ris H.B., et al. Lack of antitumor activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melaphalan in a nude mouse human melanoma xenograft system. Melanoma Research 7 Suppl 2 (1989) S43-S49
35. Van de Wiel P.A., Blocksma N., Kuper C.F., et al. Macroscopic and microscopic early effects of tumour necrosis factor on murine Meth A sarcoma, and relation to curative activity. J Pathol 157 (1989) 65-73
36. Fajardo L.F., Kwan H.H., Kowalski J., et al. Dual role of tumor necrosis factor-alpha in angiogenesis. Am J Pathol 140 (1992) 539-544
37. Balkwill F.R., Lee A., Aldam G., et al. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res 46 (1986) 3990-3993
38. Watanabe N., Niitsu Y., Umeno H., et al. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res 48 (1988) 2179-2183
39. Fujuwara H., Yamauchi N., Sato Y., et al. Synergistic suppressive effect of double transfection of tumor necrosis factor-a and interleukin 12 genes on tumorigenicity of Meth-A cells. Jpn J Cancer Res 91 (2000) 1296-1302
40. Levitsky H.I., Lazenby A., Hayashi R.J., and Pardoll D.M. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 179 (1994) 1215-1224
41. Imboden M., Murphy K.R., Rakhmilevich A.L., et al. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy. Cancer Res 61 (2001) 1500-1507
42. Garcia-Lora A., Algarra I., and Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 195 (2003) 346-355
43. Algarra I., Collado A., and Garrido F. Altered MHC class I antigens in tumors. Int J Clin Lab Res 27 (1997) 95-102
44. Tanaka K., Yoshioka T., Bierberich C., and Jay G. Role of the major histocompaibility complex class I antigens in tumor growth and metastasis. Annu Rev Immunol 6 (1988) 359-380